{
    "clinical_study": {
        "@rank": "63670", 
        "arm_group": {
            "arm_group_label": "KHK4827", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is an open-label, non-controlled study to evaluate the efficacy and safety of\n      KHK4827 in subjects with pustular psoriasis (generalized) and psoriatic erythroderma.\n      Pharmacokinetics of KHK4827 will also be assessed."
        }, 
        "brief_title": "An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has signed voluntarily the written informed consent form to participate in\n             this study.\n\n          -  Subject has been diagnosed as pustular psoriasis or psoriatic erythroderma.\n\n          -  Subject has received at least one previous phototherapy or systemic psoriasis therapy\n             or has been a candidate to receive phototherapy or systemic psoriasis therapy in the\n             opinion of the investigator.\n\n        Exclusion Criteria:\n\n          -  Subject with psoriatic erythroderma has involved Body surface area (BSA) of lesion <\n             80% at baseline.\n\n          -  Subject diagnosed with guttate psoriasis, medication-induced or\n             medication-exacerbated psoriasis.\n\n          -  Evidence of skin conditions at the time of the screening visit (eg, eczema) that\n             would interfere with evaluations of the effect of KHK4827 on psoriasis.\n\n          -  Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2\n             or higher infection\n\n          -  Subject has a significant concurrent medical condition or laboratory abnormalities,\n             as defined in the study protocol.\n\n          -  Subject has used Ultra Violet B (UVB) therapy within 14 days of the first dose or\n             Ultra Violet A (UVA) (with or without psoralen) within 28 days of the first dose.\n\n          -  Subject has used etanercept, adalimumab, infliximab or ustekinumab within 1 week,  2\n             weeks, 8 weeks or 12 weeks of the first dose, respectively.\n\n          -  Subject has stopped ustekinumab or other anti-Interleukin (IL)-23 biologics therapy\n             due to lack of efficacy\n\n          -  Subject has used live vaccine within 3 months of the first dose\n\n          -  Subject has previously used an anti-IL-17 biologic therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782937", 
            "org_study_id": "4827-004"
        }, 
        "intervention": {
            "arm_group_label": "KHK4827", 
            "description": "140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)", 
            "intervention_name": "KHK4827", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chiyoda-ku", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "100-8185"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Long-Term Study of KHK4827 in Subjects With Pustular Psoriasis (Generalized) and Psoriatic Erythroderma", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CGI is a 4-point scale that requires the investigators/subinvestigators to assess how much the subject's illness has improved or worsened relative to a baseline state. Scores on the scale are rated as: 1, remission; 2, improved; 3, no change; 4, worsened", 
            "measure": "Clinical Global Impression (CGI)", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent improvement from baseline in Psoriasis Area and Severity Index (PASI)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "American College of Rheumatology (ACR) 20 (only in subjects with psoriasis arthritis)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Pustular symptom score (only in subjects with pustular psoriasis)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Static physician's global assessment (sPGA) of \"clear or almost clear (0 or 1)\" at Week 12 (only in subjects with psoriatic erythroderma)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "sPGA of \"clear (0)\" at Week 12 (only in subjects with psoriatic erythroderma)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Body surface area involvement (BSA) of lesion at Week 12 (only in subjects with psoriatic erythroderma)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Incidence and types of adverse events and adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Laboratory values and vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "Concentration of KHK4827 in serum", 
                "measure": "Profiles of pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Development of anti-KHK4827 antibody", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Kyowa Hakko Kirin Company, Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Company, Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}